Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Lexaria BioscienceLEXX +3.69%22 Current Ratio is 10.61 as of May. 2026, which is 49% below its 10-year median of 20.66. GuruFocus rates LEXX with a GF Score™ of 22/100 and a GF Value™ of $0.37 (Significantly Overvalued). The stock has 4 warning signs investors should review. Among 1,408 Biotechnology companies, Lexaria Bioscience ranks better than 79.83% on this metric.
The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. Lexaria Bioscience's current ratio for the quarter that ended in May. 2026 was 10.61.
Lexaria Bioscience has a current ratio of 10.61. It indicates the company may not be efficiently using its current assets or its short-term financing facilities. This may also indicate problems in working capital management.
The historical rank and industry rank for Lexaria Bioscience's Current Ratio or its related term are showing as below:
LEXX'
s Current Ratio Range Over the Past 10 Years
Min: 1.18 Med: 20.66 Max: 81.33
Current: 10.61
During the past 13 years, Lexaria Bioscience's highest Current Ratio was 81.33. The lowest was 1.18. And the median was 20.66.
LEXX's Current Ratio is ranked better than 79.83% of 1408
companies
in the Biotechnology industry
Industry Median: 3.88
vs LEXX: 10.61
Lexaria Bioscience (NAS:LEXX) Current Ratio Explanation
The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.
Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.
The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.
If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.
Lexaria Bioscience Current Ratio Related Terms
Lexaria Bioscience Current Ratio Historical Data
* Premium members only.
The historical data trend for Lexaria Bioscience's Current Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Lexaria Bioscience's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Lexaria Bioscience Current Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Lexaria Bioscience's Current Ratio distribution charts can be found below:
* The bar in red indicates where Lexaria Bioscience's Current Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Lexaria Bioscience (LEXX) has a Current Ratio of 10.61 as of May. 2026. This is 49% below median its historical median of 20.66. Over the past decade, Lexaria Bioscience's Current Ratio has ranged from 1.18 to 81.33. According to the industry distribution chart, Lexaria Bioscience ranks #284 out of 1408 companies in the Biotechnology industry, placing it in the top 20.2%.
Is Lexaria Bioscience's Current Ratio too high?
Lexaria Bioscience's current Current Ratio of 10.61 is 49% below median its 10-year median of 20.66. Over the past 10 years, this metric has ranged from a low of 1.18 to a high of 81.33. The Biotechnology industry median Current Ratio is 3.88. Lexaria Bioscience's value of 10.61 is 173.5% above this industry median. Based on the distribution chart, Lexaria Bioscience ranks #284 out of 1408 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Lexaria Bioscience has a GF Score™ of 22/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Lexaria Bioscience's Current Ratio compare to CTXR and PTN?
According to the Biotechnology industry distribution chart, Lexaria Bioscience ranks #284 out of 1408 companies for Current Ratio. This places Lexaria Bioscience in the top 20% of its industry — outperforming the majority of peers. The industry median Current Ratio is 3.88. Lexaria Bioscience's value of 10.61 is 173.5% above this benchmark. Historically, Lexaria Bioscience's own Current Ratio has ranged from 1.18 to 81.33 over the past decade. While the company's 10-year median is 20.66 vs. the industry median of 3.88, Lexaria Bioscience has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Ratio for a Biotechnology company?
The median Current Ratio among Biotechnology companies is 3.88, based on 1,408 companies in the industry. Companies in the top quartile (top 25%) have a Current Ratio significantly above this median, while those in the bottom quartile fall well below. However, Current Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Lexaria Bioscience's current Current Ratio of 10.61 is 173.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Ratio mean?
A high Current Ratio can signal that a stock is expensive relative to its fundamentals. For the Biotechnology industry, the median Current Ratio is 3.88 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Lexaria Bioscience's current Current Ratio is 10.61, which is 49% below median its own 10-year median of 20.66. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lexaria Bioscience stock overvalued right now?
Based on GuruFocus' analysis, Lexaria Bioscience (LEXX) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.37, compared to a current price of $0.54 — trading 46% above its estimated fair value. The current Current Ratio is 10.61, which is 49% below median its 10-year median of 20.66 and 173.5% above the Biotechnology industry median of 3.88. Lexaria Bioscience's overall GF Score™ is 22/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Ratio calculated?
Current Ratio is calculated from a company's financial statements. For Lexaria Bioscience (LEXX), the current Current Ratio is 10.61 as of May. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Lexaria Bioscience (LEXX) Overvalued in 2026?
Based on GuruFocus' analysis, Lexaria Bioscience stock appears to be overvalued.
The current stock price of $0.54 is trading 46% above its estimated GF Value™ of $0.37.
GuruFocus considers Lexaria Bioscience to be Significantly Overvalued.
Key valuation signals for LEXX:
Current Ratio: 10.61 (49% below median its 10-year median of 20.66)
GF Value™: $0.37 vs. price of $0.54 (46% above fair value)
Industry Position: 173.5% above the Biotechnology median (#284 of 1408)
No single metric tells the full story. See the LEXX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Lexaria Bioscience Corp is a biotechnology company focused on enhancing the bioavailability of active pharmaceutical ingredients using its patented DehydraTECH drug delivery technology. DehydraTECH improves absorption, effectiveness, and tolerability and can be applied to APIs such as GLP-1 and GIP drugs, vitamins, pain medications, hormones, antivirals, nicotine and cannabinoids across therapeutic areas including diabetes, weight loss, epilepsy, hypertension, and heart disease. It can be used in formats such as tablets, capsules, oral suspensions, foods, beverages, and pouches, and supports pharmaceuticals, nutraceuticals, over-the-counter products, and consumer packaged goods. The Company operates one segment: IP licensing, generating revenue from licensing its DehydraTECH technology.
22GF Score
Get the complete analysis for LEXX
Current Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LEXX has been successfully added to your 
